

Jan Lycke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6172109/jan-lycke-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

5,314
citations

34
h-index

72
g-index

99
ext. papers

6,755
ext. citations

6.8
avg, IF

5.28
L-index

#	Paper	IF	Citations
90	Smouldering multiple sclerosis: the real MSU. <i>Therapeutic Advances in Neurological Disorders</i> , 2022 , 15, 17562864211066751	6.6	5
89	Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. <i>Therapeutic Advances in Neurological Disorders</i> , 2022 , 15, 175628642210903	6.6	
88	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 3316-3324	5.5	0
87	Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102842	4	2
86	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2021 , 10, 803-818	4.6	0
85	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
84	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 189-194	5.5	4
83	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. <i>Neurology</i> , 2021 , 96, e1574-e1584	6.5	2
82	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 52, 102977	4	
81	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. <i>JAMA Neurology</i> , 2021 , 78, 1197-1204	17.2	16
80	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211039104	5	1
79	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. <i>Journal of Neurochemistry</i> , 2021 , 159, 618-628	6	7
78	Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden. <i>Journal of Medical Economics</i> , 2021 , 24, 770-780 ^{2,4}		0
77	Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102253	4	1
76	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12952-12960	11.5	39
75	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020 , 94, e2457-e2467	6.5	29
74	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14

73	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology, The</i> , 2020 , 19, 307-316	24.1	77
72	Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420929467	6.6	27
71	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020 , 94, e1201-e1212	6.5	46
70	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. <i>Annals of Neurology</i> , 2020 , 87, 688-699	9.4	43
69	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1719-1728	5	8
68	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1866-1876	5	12
67	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2020 , 19, 988-997	24.1	28
66	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102463	4	6
65	Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. <i>Clinical Chemistry</i> , 2020 , 66, 1228-1237	5.5	4
64	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. <i>JAMA Neurology</i> , 2020 , 77, 184-191	17.2	200
63	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1532-1539	5	6
62	An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3565-3572	5.1	7
61	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. <i>Acta Neurologica Scandinavica</i> , 2019 , 139, 422-427	3.8	3
60	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. <i>Journal of Neuroinflammation</i> , 2019 , 16, 16	10.1	13
59	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
58	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. <i>European Journal of Neurology</i> , 2019 , 26, 1060-1067	6	19
57	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. <i>Scientific Reports</i> , 2019 , 9, 17309	4.9	1
56	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS. <i>Journal of Neurochemistry</i> , 2018 , 146, 322-332	6	7

55	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 143-150	3.8	13
54	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018 , 391, 1263-1273	4.0	422
53	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
52	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1046-1054	5	113
51	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. <i>PLoS ONE</i> , 2018 , 13, e0194828	3.7	21
50	054 Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A22.2-A22	5.5	
49	A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland. <i>Journal of Neurology</i> , 2018 , 265, 108-114	5.5	7
48	A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, S10-S10		
47	P.027 Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, S23-S23	1	
46	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 62-71	5	64
45	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017 , 89, 2230-2237	6.5	205
44	Trials of antivirals in the treatment of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017 , 136 Suppl 201, 45-48	3.8	11
43	The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 1143-1153	5.1	14
42	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017 , 141, 296-304	6	87
41	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. <i>Acta Neurologica Scandinavica</i> , 2017 , 135, 17-24	3.8	37
40	PO152 Alemtuzumab efficacy in patients with relapse after course 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A53.1-A53	5.5	
39	High Interferon- γ Uniquely in V α T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017 , 8, 260	8.4	11
38	Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. <i>Neurology</i> , 2016 , 87, 2074-2081	6.5	187

37	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1587-1595	5	53
36	Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 212-21	5	47
35	Rituximab in paediatric onset multiple sclerosis: a case series. <i>Journal of Neurology</i> , 2016 , 263, 322-326	5.5	30
34	Minocycline added to subcutaneous interferon β 1a in multiple sclerosis: randomized RECYCLINE study. <i>European Journal of Neurology</i> , 2016 , 23, 861-70	6	24
33	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016 , 79, 950-8	9.4	143
32	Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. <i>Journal of the Neurological Sciences</i> , 2016 , 370, 123-131	3.2	9
31	Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015 , 353, 155-7	3.2	12
30	Age-dependent effects on the treatment response of natalizumab in MS patients. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 48-56	5	17
29	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015 , 358, 201-6	3.2	19
28	Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. <i>Therapeutic Advances in Neurological Disorders</i> , 2015 , 8, 274-93	6.6	29
27	Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis. <i>Neuroepidemiology</i> , 2015 , 45, 83-9	5.4	7
26	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
25	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1116-21	5.5	108
24	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 43-50	5	81
23	First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. <i>Journal of Neurology</i> , 2014 , 261, 2016-8	5.5	10
22	CSF levels of YKL-40 are increased in MS and reduces with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014 , 269, 87-9	3.5	43
21	High nationwide incidence of multiple sclerosis in Sweden. <i>PLoS ONE</i> , 2014 , 9, e108599	3.7	41
20	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013 , 45, 1353-60	36.3	934

19	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 765-74	5	58
18	Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. <i>Journal of Neurology</i> , 2011 , 258, 882-8	5.5	96
17	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. <i>Annals of Neurology</i> , 2011 , 69, 83-9	9.4	236
16	High nationwide prevalence of multiple sclerosis in Sweden. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 901-8	5	130
15	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 708-19	5	80
14	Autism spectrum disorders: does cilia dysfunction in embryogenesis play a role?. <i>Acta Neuropsychiatrica</i> , 2008 , 20, 227-228	3.9	2
13	Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. <i>Neurology</i> , 2003 , 61, 1720-5	6.5	239
12	Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 2438-41	5.9	79
11	Asymptomatic visual loss in multiple sclerosis. <i>Journal of Neurology</i> , 2001 , 248, 1079-86	5.5	22
10	Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. <i>Journal of Neurology</i> , 1996 , 243, 214-24	5.5	93
9	Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. <i>Journal of the Neurological Sciences</i> , 1995 , 133, 61-5	3.2	82
8	Human spumaretrovirus antibody reactivity in multiple sclerosis. <i>Journal of Neurology</i> , 1994 , 241, 204-9	5.5	10
7	Possible association of HTLV-I infection and dementia. <i>Acta Neurologica Scandinavica</i> , 1993 , 88, 199-203	3.8	6
6	Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope. <i>Journal of Neurology</i> , 1993 , 240, 381-7	5.5	28
5	Use of immunoreactive synthetic HTLV-1 peptides in the search for antibody reactivity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1992 , 85, 44-54	3.8	4
4	No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1992 , 32, 711-4	9.4	11
3	Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. <i>Acta Neurologica Scandinavica</i> , 1990 , 82, 161-8	3.8	80
2	Acyclovir concentrations in serum and cerebrospinal fluid at steady state. <i>Journal of Antimicrobial Chemotherapy</i> , 1989 , 24, 947-54	5.1	30

1 Diagnostic value of plasma neurofilament light: A multicentre validation study

6